The CYP3A locus encodes hepatic enzymes that metabolize many clinically used drugs. However, there is marked interindividual variability in enzyme expression and clearance of drugs metabolized by these enzymes. We utilized comparative genomics and computational prediction of transcriptional factor binding sites to evaluate regions within CYP3A that were most likely to contribute to this variation. We then used a haplotype tagging singlenucleotide polymorphisms (htSNPs) approach to evaluate the entire locus with the fewest number of maximally informative SNPs. We investigated the association between these htSNPs and in vivo CYP3A enzyme activity using a single-point IV midazolam clearance assay. We found associations between the midazolam phenotype and age, diagnosis of hypertension and one htSNP (141689) located upstream of CYP3A4. 141689 lies near the xenobiotic responsive enhancer module (XREM) regulatory region of CYP3A4. Cell-based studies show increased transcriptional activation with the minor allele at 141689, in agreement with the in vivo association study findings. This study marks the first systematic evaluation of coding and noncoding variation that may contribute to CYP3A phenotypic variability.
Introduction
The genes encoding the CYP3A subfamily are located on chromosome 7 and span 200 kilobases (kb). This gene family consists of four members, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, which encode enzymes responsible for the metabolism of approximately 50% of current drugs, as well as many endogenous substances. 1, 2 CYP3A4 is the major isoform in adult humans, and is expressed mainly in the liver and intestinal epithelium. It can metabolize a wide range of substrates and thus variability in its expression or activity may have significant clinical consequences. CYP3A5 is expressed in the liver, intestine 3 and kidney, 4 and has similar substrate specificity to CYP3A4. CYP3A5 has large interindividual variability in expression due to an intronic single-nucleotide polymorphism (SNP), which results in a truncated nonfunctional protein. This SNP has dramatic differences in allele frequency across populations, 5 with the most common nonfunctional allele, CYP3A5*3, occurring at high frequency in non-African populations. CYP3A7 is the fetal CYP3A enzyme that is rapidly downregulated after birth. Although CYP3A43 is ubiquitously expressed at low levels throughout the body, its role in drug metabolism is not well understood.
These enzymes have clear interindividual differences in activity. Several studies have shown that microsomal CYP3A4 content can vary anywhere from 10-to 100-fold, [6] [7] [8] though the distribution of this variation is unimodal. 9 This unimodal distribution suggests that simple monogenic control of CYP3A4 expression is unlikely. 10, 11 In a study of healthy volunteers, the heritability of the observed enzyme variability of CYP3A4 has been estimated at 90%, 12 suggesting an important role of genetic variation at the CYP3A locus or in genes coding for the transcription factors regulating CYP3A expression. Several coding SNPs have been identified in the CYP3A locus, but they explain only a minor portion of the variation seen in levels of expression or in activity as measured by probe drugs. 13, 14 However, these association studies focused on a limited number of common CYP3A SNPs, usually in the coding region or untranslated regions, and were not based on SNPs detected through a systematic and comprehensive survey of sequence variation at the CYP3A gene cluster.
Sequence variation at the CYP3A gene cluster was recently surveyed in ethnically diverse population samples. This survey aimed at uncovering sequence variation in both coding and noncoding regions that are likely to harbor sequence elements regulating CYP3A expression. The identification of such elements was achieved by a combination of comparative genomics and computational analysis. More specifically, the sequence of the entire CYP3A gene cluster was compared across five mammalian species, spanning over 300 million years of evolutionary time, which revealed many strongly conserved sequences. 15 The comparative genomics approach was combined with computational prediction of clusters of liver-enriched transcription factor (LETF) binding sites within the CYP3A noncoding sequence; such clusters may signal a true regulatory region, as opposed to computationally predicted single sites, which occur at high frequency throughout the genome and are likely to be false positives. Although not all the sequence elements detected by these two approaches are expected to affect expression, combining these approaches greatly increases the probability of identifying regulatory elements; as a consequence, sequence variants within such elements may underlie some of the observed variation in CYP3A expression. By resequencing these elements in samples of African Americans, European Americans and Chinese Americans, it was shown that there are unusually large differences in the haplotype structure and allele frequencies between AfricanAmerican and non-African population samples. Importantly, the amount of variation was much greater in the African-American sample compared to the samples of nonAfrican ancestry.
This study aims to determine whether the variability in CYP3A expression and activity is due to genetic variation at the CYP3A locus. Because of greater genetic variation in African Americans compared to non-Africans, we decided to focus on African Americans as our target population. In order to capture a large amount of CYP3A sequence variation, we selected haplotype tagging SNPs (htSNPs) among those detected in the above resequencing study. These htSNPs represent the minimal set of maximally informative SNPs required to capture the haplotype diversity at the CYP3A locus in any given population. As a marker of CYP3A activity, we used a single-point plasma measurement of the ratio of the primary metabolite of midazolam (1 0 -OH midazolam) to midazolam. This phenotype has been used extensively as both a probe for CYP3A activity as well as specifically for CYP3A4 activity. [16] [17] [18] As in vitro studies have shown that both CYP3A4 and CYP3A5 play a role in midazolam hydroxylation, this is the ideal probe for CYP3A activity. 9 Importantly, it was shown that this ratio is strongly correlated with CYP3A4 content (r 2 ¼ 0.87) 19 and with midazolam clearance (r 2 ¼ 0.89). 20 Moreover, the midazolam hydroxylation ratio has been used in several other phenotype/genotype association studies for CYP3A4, 16, [21] [22] [23] the results of which can be compared to the results obtained in our study. In vitro cell-based assays and liver mRNA studies were conducted to confirm the regulatory role of the htSNPs found to be significant in this study.
Results
We recruited 135 African-American outpatients to determine the effect of CYP3A variation on the midazolam metabolite ratio using the liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) procedure described in the Methods Section. Figure 1 shows the distribution of this phenotype, with a mean of 0.075 and a standard deviation of 0.062. We observed a 20-fold range in the midazolam phenotype, which is consistent with other studies on CYP3A4 activity. [24] [25] [26] Most of these studies found that variation in CYP3A activity ranged between 10-and 30-fold. Because of the non-normal distribution of the phenotype, the data were transformed using a natural log in all statistical analysis.
The median age of the study population was 61 years, and ranged from 21 to 88 years of age. There were also a higher number of women in this study than men (86 vs 49, respectively). However, the midazolam phenotype showed no correlation with sex (P ¼ 0.24). A total of 60% of the study population had a diagnosis of hypertension upon entry into the study (as assessed by chart review, medication review and patient interview) which was significantly related (by analysis of variance (ANOVA) analysis) to the midazolam phenotype (P ¼ 0.007). In addition there was a correlation between age and midazolam phenotype (P ¼ 0.0003). Both of these variables were used as covariates in subsequent analyses. No other statistically significant correlations were found with any of the other demographic information.
In order to select htSNPs, we analyzed the data from a resequencing survey in a sample of 24 African Americans. We included all SNPs found in this survey with a minor allele frequency (MAF) greater than 10% and set the minimum correlation coefficient between SNPs (r 2 ) to 0.8. Table 1 shows the location and sequence context of the htSNPs used in this study. The MAF cutoff was chosen to omit rare SNPs, for which there is limited power to detect a phenotypic correlation. This analysis identified 26 htSNPs, of which 19 belong to singleton bins (that is no other SNP had a correlation coefficient greater than 0.8). Because of sequence context and constaints of the genotyping platforms used, one htSNP could not be genotyped. As shown in Figure 2 , the allele frequencies in the present study population and the original resequencing sample are very similar. As with allele frequencies, the linkage disequilibrium (LD) patterns between htSNPs in the original resequencing data (Figure 3a) and in the present genotyping data (Figure 3b ) are very similar. In both data sets, there is little LD between htSNPs, which is expected because they were selected to have relatively low correlation coefficients in the resequencing survey. However, two pairs of htSNPs (83269 and 88726 in CYP3A43 and 280707 and 283714 CYP3A5) were more strongly correlated in our genotyping data compared to the resequencing data. This may be due to variation across samples, or to the substantial difference in sample size (24 vs 135 in the resequencing and the present genotyping studies, respectively). In addition, because the degree of African ancestry in each sample is unknown, it is possible that the differences in LD between the two are due to subtle differences in population structure.
To determine if any htSNP or combination of htSNPs significantly explained the variation seen in the midazolam ratio, we used general linear model (GLM) univariate analysis. The results of this analysis are presented in Table 2 . The entire model, including hypertension and age as covariates, was significant (P ¼ 0.029) with an r 2 of 0.474, as well as one htSNP, 141689 (P ¼ 0.011). Interestingly, when hypertension and age are removed from the analysis the model is no longer significant; however the htSNP 141689 is still significant. This SNP is located 7 kb upstream of the CYP3A4 transcription start site, therefore, it stands as a plausible candidate for variation in CYP3A4 expression levels. ANOVA analysis of this SNP shows that the minor T allele is associated with a higher midazolam ratio (that is high CYP3A activity). MATCH analysis at this SNP was conducted and the results are presented in Table 3 , along with the effect of the derived allele to the retention destruction and/or creation at each site. From this analysis we see that the derived allele (T allele) results in the destruction of two of the eight putative transcriptional binding sites as well as the creation of a new CCAAT displacement protein/cut repeat 3 (CDPCR3) site.
We also tested whether variants known to affect CYP3A5 expression (CYP3A5*3, *6 and *7) as a group are correlated with hypertension or midazolam ratio. The ANOVA analysis Shaded row indicates significant SNP in univariate analysis.
CYP3A4 enzyme activity in African Americans
MA Perera et al looking at the association between hypertension and the number of functional copies of CYP3A5 was not significant. We analyzed the intergenic sequence between CYP3A4 and CYP3A43 genes. The sequence for this genomic region was not included in the original resequencing, hence, we had no information about whether the variation in this region was tagged by htSNPs we genotyped in this study. In this region, we identified two high-probability clusters of predicted binding sites for LETFs. These two peaks were located at nucleotide positions 132736À133806 and 136085À136601 respectively (that is approximately 13 and 16 kb upstream of the CYP3A4 transcriptional start site). These clusters may reflect the presence of a sequence element regulating CYP3A expression, but they have not been surveyed for sequence variation. Therefore, we selected 16 individuals with the lowest midazolam ratio and 16 individuals with the highest midazolam ratio; these samples identify the top and bottom 12% of the phenotypic distribution. The two segments containing the clusters of predicted TF binding sites were resequenced in each of the 32 individuals to assess differences in allele frequency and haplotypes between the extremes of the phenotypic distribution. We compared the allele frequency distributions of these novel SNPs between the upper and lower tails of the phenotype distribution. No significant allele frequency differences were found. We also used PHASE (version 2.0) to infer haplotypes and determine haplotype association with phenotype for these SNPs using the case-control test to assess association. The test compares haplotype distributions between two groups to determine if any difference in distribution exists. No significant association was detected. In addition, we used MATCH to determine the location and core sequence of putative transcriptional binding sites and identified four novel SNPs in this region. Table 4 shows the position of each of these SNPs and the predicted effect on transcriptional binding sites. From this analysis we found that three sites were destroyed (two hepatic nuclear factor3b (HNF3b) sites and one C/EBP-b site) and one site created (TATA site) by the minor alleles at these locations.
To evaluate the effect of the htSNP 141689 SNP on transcription, human HepG2 and LS180 cells were transfected with the À13 kb CYP3A4-LUC wt (wild type) and variant plasmids ( Figure 4 ). The variant 141689T allele showed higher basal activity in both the liver and intestinal cell model. Moreover, the pregnane X receptor (PXR) and rifampin-induced transcriptional activities (PXR and rifampin alone and in combination) of the 141689T allele were significantly higher than the 141689G allele in both the LS180 and HepG2 cells. African-American donor livers were genotyped to determine the effect of htSNP 141689 on hepatic CYP3A4 mRNA levels. Among male African-American livers (n ¼ 32), those heterozygous at 141689 showed somewhat higher levels of CYP3A4 mRNA compared to the homozygous 141689 TT samples (Figure 5a ). However, the 141689 TT homozygote livers had a significantly lower CYP3A4 mRNA levels compared to livers with at least one 141689G allele. Similar results were seen when the analysis was performed in the combined group of male and female African-American donor livers (n ¼ 48) (Figure 5b ). These findings contradict our in vivo phenotype-genotype association results and the cell-based transcriptional activation results. This may be due to the unknown drug and disease status of some of the liver donors used in this study. 
Discussion
Studies of CYP3A haplotypes have been limited to genotyping of functional alleles, 27 or genotyping SNPs interspersed throughout the locus. 28 By using a htSNPs approach based on a full resequencing study of conserved sequences across distantly related species, the present study represents the first systematic and comprehensive test of the contribution of genetic variation within the CYP3A gene cluster to variation in CYP3A enzyme function. In this study we found a significant association between the midazolam ratio phenotype with htSNP 141689 found À7206 bp upstream of CYP3A4. Further cell-based in vitro studies showed that the 141689T allele was associated with increased basal and PXR inducible CYP3A4 transcriptional activity, suggesting a role for this SNP in basal and inducible CYP3A4 hepatic expression.
Because of the significant association, we used MATCH analysis to infer the role of htSNP 1415689 in transcription factor binding (results shown in Table 3 ). The most notable of these is the destruction of the peroxisome proliferatoractivated receptor (PPAR)a/retinoid X receptor (RXR)a and GATA-4 sites and the creation of the CDPCR3 site. Induction of CYP3A4 by endogenous compounds such as steroidal hormones or xenobiotics is known to be mediated by constitutive androstane receptor (CAR), 29, 30 PXR 31, 32 and the vitamin D receptor. 33 Constitutive expression of CYP3A4 may also be regulated through these nuclear receptors. 34 Both PXR and CAR require interaction with RXRa to regulate transcription. Animal studies have shown that mice deficient in RXRa have reduced basal expression of CYP3A4. 35 PPARa is known to form a heterodimer with RXRa and regulates CYP4A expression in mice. 36 However, this regulatory mechanism was not seen in human hepatocyte cultures. 37 Further studies are needed to determine the role of these TFB sites and cognate binding factors to CYP3A4 regulation. It should be noted that htSNP 141689 (À7206) is located just downstream of the XREM regulatory region (À7836 to À7607 bp upstream of the transcriptional start site) of CYP3A4. This region, in conjunction with a proximal XREM directs PXR and CAR-mediated transcription of CYP3A4. 38 Currently the role of the PPARa/RXRa heterodimer, GATA-4 and CDPCR3 are not known in relation to CYP3A regulation. Although the CYP3A4 5 0 -flanking region is more than 35.8 kb in length, most regulatory studies have focused on the proximal 12 kb sequence immediately upstream of the gene. In a study by Matsumura et al. 39 focused on the region 12 kb upstream of CYP3A4, the investigators identified the constitutive liver enhancer module of CYP3A4 (CLEM4) located 11.5 kb upstream of the CYP3A4 gene. However, in our study we resequenced regions between CYP3A4 and CYP3A43, which has not been previously investigated. MATCH analysis of the four novel SNPs found in this region revealed that these SNPs are predicted by in silico analysis to affect putative transcription factor binding sites for HNF3b and C/EBP-b, and one SNP leads to the creation of a TATA site. The HNF-3 proteins are involved in the regulation of numerous liver-specific genes. 40 An HNF3b site has previously been identified À195 to À186 bp upstream of CYP3A4 and disruption of this site caused downregulation of basal CYP3A4 expression in transient transfection assays. 41 As the HNF3b sites found in our analysis are further upstream than those in previous work, further in vitro studies are needed to determine the role of these regions in regulation of the CYP3A locus.
In this study we included SNPs within CYP3A5 that are known to cause a loss of function. The most highly studied, CYP3A5*3 within intron 3 of the gene, creates a cryptic slice site resulting in a nonfunctional protein. This nonfunctional variant is at high frequency in Caucasians, with approximately 10-30% of individuals in this population expressing CYP3A5, whereas approximately 60% of African American express CYP3A5. 5, 42 In addition, two other loss of function variants, CYP3A5*6 and CYP3A5*7, are found solely in populations of African ancestry. 43 Although none of these SNPs alone or in combination with other htSNPs were shown to contribute significantly to phenotype Figure 6 Predicted TFB sites in the CYP3A intergenic region. Graphical analysis by Cister shows the location of TFB sites between CYP3A4 and CYP3A43. The peaks represent TFB site cluster probability with each TFB site shown as a designated colored line within each peak. The location of each peak is marked as distance upstream from CYP3A4 transcriptional start site. variation in our study, the effect of these SNPs on drug metabolism is not entirely clear. Although the CYP3A5*3 variant has shown clear association with midazolam metabolism in vitro, 5, 9, 44 the in vivo evidence is contradictory, with a bulk of the studies showing no association of midazolam metabolism with CYP3A5 genotype. 17, [45] [46] [47] [48] Clearly the role of both CYP3A4 and CYP3A5 in midazolam metabolism is complex and may involve variation in the regulation of these genes, 9 or difference in CYP3A4 content related to CYP3A5 genotype. 49 During our initial analysis, we found an association of hypertension to the midazolam metabolite ratio. This finding was interesting given the numerous studies looking at the role of CYP3A5 and hypertension. Significant associations have been found in studies looking directly at the association of the hypertension phenotype in African Americans to the known functional SNPs in CYP3A5.
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A previous publication from our laboratory showed that, like other variants influencing risk to hypertension, 53 CYP3A5*1 has large population difference in allele frequency and has a strong latitudinal cline with populations close to the equator having moderately high frequency of the allele whereas populations at latitudes further from the equator have low allele frequencies. 54 It was postulated that this may be due to a selective advantage for salt retention in hot climates that have scarce water supplies, which may contribute to salt-sensitive hypertension in populations of African ancestry. In contrast with these findings, our data did not show a significant association between the number of functional copies of CYP3A5 and either hypertension or the midazolam phenotype. This negative result may simply be due to insufficient power, or the inability to classify the type of hypertension within our study population. A systematic evaluation of salt-sensitive hypertension in African-Americans and CYP3A variants is needed to definitively answer this question.
Both the in vivo clinical genotype/phenotype study and the in vitro transcriptional cell-based assay show an association of the htSNP 141689 with increased CYP3A4 enzyme activity. However the in vitro liver mRNA study showed contradictory results. This may be due to several factors, namely the unknown drug and disease status of the liver donors. In the clinical genotype/phenotype study a thorough evaluation of each subject's drug and disease status was performed before inclusion. If a subject had a disease which could affect drug clearance and/or enzyme function (such as liver or renal dysfunction) they were excluded from the study. In addition, any subject on drugs which induced or inhibited CYP3A was excluded. In this way the clinical phenotype/genotype study allowed more conclusive evaluation of the CYP3A phenotype given the strict inclusion criterion.
If, indeed, this SNP lies within a regulatory element responsible for constitutive activity of CYP3A4, this element may have alternate function in an induced or inhibited environment. The cell types used may also explain these results. Maruyama et al. 55 showed differential mRNA expression of CYP3A4 in HepG cells compared to human fetal liver cells in induced states, with the human fetal liver cell showing increase in mRNA to the known CYP3A4 inducer rifampin and no change seen in the fetal liver cells. In addition, degradation of enzyme due to harvesting and cold storage may also play a factor in these results. 46 There are a few limitations to the current study. First, a replication cohort would provide definitive answers to the involvement of the SNP at position 141689 in the regulation of the CYP3A locus. However, such replication studies are fiscally prohibitive and few investigators conduct studies in exclusively African-American populations. This study reflects the first association study based on population genetics and comparative genomics data from a systematic survey of CYP3A sequence variation. 15 The hope is that our study will serve as hypothesis generation for further investigations into the role on noncoding variation at this locus. Secondly, the contradictory findings of the in vitro liver study also limit the definitive association of this SNP with the regulation of the CYP3A locus. However, as stated previously, the unknown drug and disease status of the liver donors as well as the experimental conditions may make this a less robust assessment of phenotype. Though inconsistencies between in vitro and in vivo findings are not uncommon in the association literature, further studies are needed to determine if the SNP at position 141689 binds the predicted transcriptional factors. Lastly, although it is possible that the association we found through the GLM was a false positive given the number of statistical tests, the confirmation of association by the cellbased assays make this less of a concern.
In conclusion, this study has provided a systematic and comprehensive investigation into the role of genetic variation in the CYP3A locus to hepatic CYP3A4 activity. We found that htSNP 141689, found À7206 upstream of the CYP3A4 gene, significantly affects the transcriptional activation and enzyme activity of CYP3A4. Further studies are needed to determine the effect of this novel CYP3A4 promoter SNP to CYP3A4 basal and inducible expression in vitro and in vivo. In addition, as the novel SNPs we identified in the CYP3A locus can still not explain the full extent of CYP3A4 human variation, our findings strengthen support for the hypothesis that SNPs in transcription factors regulating CYP3A4 are likely to be important contributors to human variation in CYP3A4 activity.
Methods

Patient population
A total of 135 African-American subjects were recruited through the Gastrointestinal Procedure Unit at the University of Chicago Hospitals, where a single intravenous dose of midazolam is commonly utilized for conscious sedation. All subjects were screened according to medication use, medical history and clinical laboratory evaluation by both chart review and patient interview. Inclusion criteria included: a single intravenous bolus dose of 2-3 mg of midazolam given within 5 min for an elective procedure, age greater than 18 years, no known concomitant medications that would inhibit or enhance the CYP3A enzymes and consent before procedure. Exclusion criteria included: multiple doses of midazolam, diagnosis of abnormal liver or renal function, abnormal renal or hepatic laboratory values (BUN, serum creatinine, liver-specific enzymes), smoking or heavy drinking, and use of interfering medications. Every subject gave written consent before dosing of midazolam and the Institutional Review Board of the University of Chicago approved this study. Two 10 ml blood samples were taken from each subject by venipuncture 30 min after midazolam dosing. Blood samples were placed in purple top Vacutainer tubes, containing ethylenediaminetetraacetic acid, and one 10 ml sample of whole blood was frozen at À20 1C for DNA extraction. The other 10 ml sample was centrifuged and the plasma was frozen at À20 1C until time of analysis.
Genotyping procedure Different genotyping methods were used depending on the type and sequence context of each SNP. A published restriction fragment length polymorphism assay was used to genotype the CYP3A5*3 polymorphism. 54 A total of 19 SNPs were genotyped at DNAprint Genomics (http:// www.dnaprint.com/), using the Orchid SNP Stream-UltraHigh Throughput (UHT) platform (primers in Supplementary Table 1 ). This method could not be optimized for six SNPs; therefore these SNPs were genotyped by either a TaqMan assay or a single base extension (SBE) assay. Because of the sequence similarities between members of this gene family and the stringent product lengths needed for these assays, all assays were performed through nested PCR. All PCR primers were designed based on the GenBank accession number NG_000004; all nucleotide positions in this publication are numbered according to this sequence.
The optimal TaqMan primer/probe set (Supplementary Table 2 ) was identified using the Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA). The TaqMan assay was carried out in a 25 ml reaction containing 1 ml of PCR Product, 1 Â Universal Master Mix (Applied Biosystems), 10 mM of each primer and 2 mM of each fluorescent probe. The reaction was run on a MJ Research thermocycler at 50 1C for 2 min, 95 1C for 10 min, followed by 35 cycles of 92 1C for 15 s and 60 1C for 1 min. Genotype analysis was performed on the ABI SDS 7700 PCR machine with ABI PRISM 7700 software, using a standard procedure of automatic allele discrimination.
SBE assays involved PCR amplification (primer in Supplementary Table 3 ) of genomic DNA followed by enzymatic cleanup with shrimp alkaline phosphatase and exonuclease I (ExoI). The final SBE reaction was carried out in a 12 ml reaction containing 1 Â Sequenase reaction buffer (GE Healthcare Bio-Science Corp., Piscataway, NJ, USA), 7.2 ml of purified PCR product, 250 mM of each ddNTP (GE Healthcare Bio-Science Corp.), 1 mM allele-specific oligonucleotide, and 2.5 U of Sequenase (GE Healthcare Bio-Science Corp.). The reaction was run on a MJ Research thermocycler at 95 1C for 2 min, followed by 60 cycles of 96 1C for 30 s, 55 1C for 30 s, and 60 1C for 30 s. Genotypes were determined by denaturing high-performance liquid chromatography (dHPLC), which involved injection of each reaction into a preheated reversed phase column (DNA-Sep; Transgenomic, San Jose, CA, USA) on a Wave 3500HT DHPLC System (Transgenomic Inc., Omaha, NE, USA). DNA was eluted on a linear acetonitrile gradient consisting of buffer A (0.1 mol l À1 triethylammonium acetate, TEAA)/buffer B (0.1 mol l À1 TEAA, 25% acetonitrile). Data acquisition was controlled by Navigator software (version 1.6.2; Transgenomic Inc.).
Phenotyping procedure
The concentrations of midazolam and its major metabolite, 1-hydroxy (1-OH) midazolam, were measured in plasma using a published liquid chromatography/mass spectrometry (LC/MS) method with some modifications. 56 Both patient samples and concentration standards were analyzed using the following method. Briefly, a 1 ml aliquot of plasma was incubated with 2000 U ml À1 b-glucuronidase to cleave the glucuronide-conjugated metabolite. Using this method we measure the concentration of both the 1-OH midazolam and the 1-OH midazolam glucuronide. Samples were then spiked with 10 ml of prazapam (100 mg ml À1 dissolved in ethanol) and extracted as previously described by Frerichs et al. 56 For each sample and standard, 100 ml was injected into the detection system for analysis. Concentration plasma standards were made by adding appropriate amounts of both midazolam and 1-OH midazolam to blank human plasma at concentrations ranging from 150 to 1 ng ml
À1
. All samples were measured in duplicate with less that CV 40.15 between samples.
The concentrations of all samples and standards were determined by an Agilent 1100 series HPLC coupled to an ABI 2000 triple quadrapole LC/MS fitted with an electrospray ionization interface. The samples were first separated using a Luna C 18 reverse-phase chromatography column (3 mm particle size, 100 Â 46 mm i.d.; Phenomenex, Torrance, CA, USA) with an isocratic mobile phase of acetonitrile:ammonium acetate (50:50, pH 4.7) at 1 ml min
. The MS conditions were optimized using a direct infusion of standard solutions prepared in mobile phase. LC/MS quantitation was performed at the following conditions: source temperature 450 1C, curtain gas 40 ml min À1 , collision gas 6 ml min À1 , nebulizer voltage 6 V, ion source 1 gas 50 ml min
, ion source 2 gas 50 ml min Resequencing of the CYP3A43-CYP3A4 intergenic region Analysis of the intergenic region between the CYP3A43 and CYP3A4 genes revealed new clusters of predicted transcriptional factor binding sites ( Figure 6 ). The two regions closest to CYP3A4, located 13 and 16 kb upstream of the gene, were resequenced in the upper and lower ends of the phenotypic distribution (total of 32 individuals) to assess genomic differences between these two groups. PCR products were cleaned using SAP and ExoI. Dye terminator sequencing was performed with the ABI Big Dye Terminator Cycle sequencing kit and the products were analyzed with an ABI 3730 automated sequencer (Applied Biosystems). The PhredPhrap-Consed package (version 5.03) was used to assemble and analyze the sequences.
Statistical analysis
We identified LD patterns and picked htSNPs using the program LDSelect, 57 which uses r 2 (a measure of LD between pairs of SNPs), to group SNPs that are highly correlated with each other. This method reduces the number of SNPs that need to be typed while still capturing the majority of the variation present in the population. Figure 7 shows the SNPs that were binned together and the htSNP chosen to tag each bin across the CYP3A locus. Seven haplotype tagging bins were identified, each spanning only one of the CYP3A genes. In addition, 19 singleton bins were found (shown as red dots); singleton bins contain SNPs that are not highly correlated to any other SNPs in the locus, but which may still explain phenotypic variation alone or in combination with other htSNPs.
We initially assessed the correlation of each demographic factor with the midazolam phenotype using ANOVA and simple regression. The demographic factors that showed a significant correlation were then used as covariates in the subsequent analyses. We then performed GLM univariate analysis to determine which htSNP best predicted the midazolam phenotype.
Because of the previously reported association between CYP3A5 variants and hypertension, 52, 58 we also looked at the correlation between hypertension and midazolam phenotype, respectively, with the nonfunctional CYP3A5 alleles, CYP3A5*3, *6 and *7, as a group. We used PHASE to infer the haplotype phase in our sample. 59 We then determined the number of functional copies of CYP3A5 for each individual. For example, if two nonfunctional alleles were found on the same chromosome, as determined by PHASE, and only the CYP3A*1 allele was found on the second chromosome, this individual would be scored as having one functional copy of CYP3A5. If, however, an individual was homozygous for any of the nonfunctional alleles or if different nonfunctional alleles were found on the two chromosomes, the individual was scored as having no functional copies of CYP3A5. Of the 270 chromosomes investigated in this study, only 3 chromosomes were found that contained two nonfunctional alleles of the same chromosome. A total of 23 individuals were heterozygous for two of these functional SNPs with the nonfunctional SNPs occurring on different chromosomes. We then used ANOVA and w 2 -analysis to look at association of the number of functional copies to the midazolam ratio and hypertension. All analyses were performed using the SPSS software package (version 15.0.0). A P-value of less than 0.05 was deemed significant, and there was no correction for the multiplicity of statistical testing.
As the human liver mRNA levels were not normally distributed, group differences were analyzed nonparametrically using the Wilcoxon's rank sum test (W) to compare binary groups (for example, GG þ GT vs TT). The KruskalWallis (KW) test was used to compare the three genotypes for each polymorphism (for example, GG vs GT vs TT). All statistical calculations were performed using statistical program R: A Language and Environment for Statistical Analysis (http://www.R-project.org).
MATCH analysis
The MATCH version 11.1 tool (TRANSFAC Professional suite, version 11.1) was used to search for potential TFB sites in the 50 bp region surrounding htSNP 141689. MATCH uses a library of nucleotide distribution matrices of aligned TF binding sequences that are obtained by in vitro selection studies to predict TF binding sites in this sequence. Our search was restricted to the use of high-quality matrices only (that is to exclude highly abundant matrices). We used the vertebrate nonredundant profile with the minSUM cutoff function. The minSUM cutoff minimizes both false positive and false negative matches. Cutoffs are based on matrix similarity scores which describe the quality of a match between a matrix and a part of the input sequence. Analogously, the core similarity denotes the quality of a match between the core sequence of a matrix (that is the five most conserved positions within a matrix) and a part of the input sequence. The core similarity and matrix similarity scores for the predicted TF binding sites are calculated using the MATCH algorithm described by Kel et al.
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Plasmids
The À13 kbCYP3A4-LUC (wt) plasmid containing the entire CYP3A4 promoter, including the proximal and distal PXR response elements, inserted in pGL3 Basic (Promega, Madison, WI, USA) was kindly provided by Dr Christopher Liddle. 38 This plasmid contained the wild-type 141689G allele. The CYP3A4 141689T variant (var) allele was created directly from À13 kbCYP3A4-Luc (wt) by site-directed mutagenesis (QuickChange; Stratagene, La Jolla, CA, USA) using a variant primer (sense primer, 5 0 -CCATTCTCCTTTAACCTG TTGACGATATCATTGGTATTTATAC-3 0 , htSNP 141689 bolded). The À13 kbCYP3A4-Luc var plasmid was sequenced to confirm base changes.
Transient transfection studies
Human hepatoblastoma cells, HepG2 (American Type Culture Collection), were grown in minimal essential medium (Alpha-MEM; Biowhittaker, Waltersville, MO, USA) containing 10% fetal bovine serum, penicillin and streptomycin. On day 1, HepG2 cells were seeded into 24-well plates at a density of 0.6 Â 10 6 cells per well. After 24 h, cells were transfected with 200 ng per well of the wild-type or variant À13 kb CYP3A4-Luc reporter plasmid by calcium phosphate method. LS180 colon carcinoma cells were seeded into 24-well plates at a density of 0.5 Â 10 6 cells per well on day 1. They were then transfected on day 2 by dissolving plasmid in OptiMEM (Life Technologies, Carlsbad, CA, USA) and transfecting using GenJet DNA in vitro transfection reagent (SignaGen, Gaithersburg, MD, USA). After 16 h, the cells were washed with OptiMEM then incubated for 24 h. Luciferase activities were measured with the Luciferase Reporter Assay Kit (Promega) on an OPTO-COMP I luminometer and normalized to total cell protein.
The experiments were repeated in triplicate. Differences in transcriptional activation were assessed by a Student's t-test.
Human livers
Institutional review boards and clinical research advisory committees at St. Jude Children's Research Hospital and the University of Pittsburgh approved the use of tissue samples from organ donors. Human liver tissue was processed through Dr Relling's laboratory at St. Jude Children's Research Hospital and was provided by the Liver Tissue Procurement and Distribution System (NIH Contract no. N01-DK-9-2310) and by the Cooperative Human Tissue Network. Total RNA was isolated from the liver tissue from organ donors (48 African-American livers (men, n ¼ 32, women, n ¼ 16) using Trizol (Invitrogen, Carlsbad, CA, USA). First, strand cDNA was prepared from 3 mg total RNA using oligo dT primers and the Invitrogen Superscript II kit. Before real-time PCR, 20 ml of cDNA was diluted to 50 ml with DEPC-treated water.
Relative quantitation of CYP3A4 mRNA by the standard curve method An ABI gene expression assay (Hs00430021_m1) was used for real-time PCR (rtPCR) quantitation of CYP3A4 mRNA levels. Human PPIA (cyclophilin A, VIC/MGB Probe, Primer Limited) was used to normalize the relative CYP3A4 mRNA expression according to the manufacturer's instructions. cDNA (2 ml) from each sample was analyzed in duplicate by rtPCR on an ABI PRISM 7900HT Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). The reaction was run using 1 ml of the 20 Â Gene Expression Assay mix along with 7 ml of DEPC-treated water and 10 ml of 2 Â Taqman Universal PCR Master mix (with Amperase UNG; TaqMan Universal PCR Master Mix) in 20 ml final volume. Standard amplification conditions consisting of 2 min (UNG activation) at 50 1C, 10 min at 95 1C followed by 40 cycles of: 15 s (denaturing) at 95 1C and 1 min (annealing/extension) at 60 1C. Standard curves (in triplicate) were prepared for each gene using cDNA from a high expression sample serially diluted over a 3125-fold range and the amounts of CYP3A4 and cyclophilin mRNA determined by interpolation. The average CYP3A4 amount was divided by the average cyclophilin amount to obtain a normalized CYP3A4 value. One of the experimental samples was then chosen as the calibrator, and each of the normalized CYP3A4 values was divided by the normalized calibrator value to get the relative CYP3A4 mRNA expression levels for the study samples.
